Hero

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

  • Lead candidate CYAD-01 continues to demonstrate encouraging clinical activity in THINK Phase 1 trial with a new complete response (CR) observed in patient with myelodysplastic syndrome (MDS)
  • Key focus to accelerate the development of CYAD-01 for the treatment of patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) or MDS, including the initiation of a Phase 2 clinical trial during second half 2019

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Letter to Shareholders - January 2019

Letter to Shareholders - January 2019

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Discover all news

Carousel

Social Feed

RT @LifeSci_PR: Christian Homsy, M.D., CEO of @CelyadSA providing input during today's #LifeSciRoundtable at #JPM19 https://t.co/qrbEg6DBbd

1 week ago

RT @LifeSci_PR: Christian Homsy, M.D., CEO of @CelyadSA providing input during today's #LifeSciRoundtable at #JPM19 https://t.co/qrbEg6DBbd

RT @LifeSci_PR: Attendees are filing in before our last #LifeSciRoundtable at #JPM19 moderated by @amirahalidrus. CEOs from @CelyadSA, Cere…

2 weeks ago

RT @LifeSci_PR: Attendees are filing in before our last #LifeSciRoundtable at #JPM19 moderated by @amirahalidrus. CEOs from @CelyadSA, Cere…

Join @CelyadSA today ,Jan 9, at the @LifeSciAdvisors 'CEO power breakfast and roundtable discussion' moderated by… https://t.co/wv84f7sQZa

2 weeks ago

Join @CelyadSA today ,Jan 9, at the @LifeSciAdvisors 'CEO power breakfast and roundtable discussion' moderated by… https://t.co/wv84f7sQZa

@CelyadSA is one of the 15 European Biotech Companies to Watch in 2019 https://t.co/hzlhpStgDy #biotech $CYAD #Immunotherapy

2 weeks ago

@CelyadSA is one of the 15 European Biotech Companies to Watch in 2019 https://t.co/hzlhpStgDy #biotech $CYAD #Immunotherapy

RT @LifeSci_PR: Christian Homsy, M.D., CEO of @CelyadSA providing input during today's #LifeSciRoundtable at #JPM19 https://t.co/qrbEg6DBbd

1 week ago

RT @LifeSci_PR: Christian Homsy, M.D., CEO of @CelyadSA providing input during today's #LifeSciRoundtable at #JPM19 https://t.co/qrbEg6DBbd

RT @LifeSci_PR: Attendees are filing in before our last #LifeSciRoundtable at #JPM19 moderated by @amirahalidrus. CEOs from @CelyadSA, Cere…

2 weeks ago

RT @LifeSci_PR: Attendees are filing in before our last #LifeSciRoundtable at #JPM19 moderated by @amirahalidrus. CEOs from @CelyadSA, Cere…

Join @CelyadSA today ,Jan 9, at the @LifeSciAdvisors 'CEO power breakfast and roundtable discussion' moderated by… https://t.co/wv84f7sQZa

2 weeks ago

Join @CelyadSA today ,Jan 9, at the @LifeSciAdvisors 'CEO power breakfast and roundtable discussion' moderated by… https://t.co/wv84f7sQZa

@CelyadSA is one of the 15 European Biotech Companies to Watch in 2019 https://t.co/hzlhpStgDy #biotech $CYAD #Immunotherapy

2 weeks ago

@CelyadSA is one of the 15 European Biotech Companies to Watch in 2019 https://t.co/hzlhpStgDy #biotech $CYAD #Immunotherapy